How cannabis legalization affects mental health and substance use in people with psychosis
Impact of cannabis legalization and commercialization on substance use and mental health outcomes in psychosis
This study looks at how the legalization and sale of cannabis affects people with psychotic disorders, especially in terms of their substance use and mental health, to help understand any risks they might face.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cambridge Health Alliance NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11032923 on NIH RePORTER |
What this research studies
This research investigates the impact of cannabis legalization and commercialization on individuals with psychotic disorders, particularly focusing on how these changes affect their substance use and mental health outcomes. The study will analyze existing data from national surveys and specialized clinics to understand the relationship between cannabis market expansion and the health of those with serious mental illnesses. By employing advanced statistical methods, the research aims to identify potential risks associated with cannabis use in this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who have been diagnosed with psychotic disorders, such as schizophrenia.
Not a fit: Patients who do not have a history of psychosis or are under the age of 21 may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of cannabis-related risks for individuals with psychosis.
How similar studies have performed: Previous research has indicated that cannabis use can exacerbate symptoms in individuals with psychosis, suggesting that this study's focus on commercialization effects is both relevant and necessary.
Where this research is happening
Cambridge, United States
- Cambridge Health Alliance — Cambridge, United States (Active)
Researchers
- Principal investigator: Hyatt, Andrew — Cambridge Health Alliance
- Study coordinator: Hyatt, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.